Sees FY26 adjusted EBITDA loss $30M-$35M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics options imply 4.2% move in share price post-earnings
- AQST Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Aquestive Highlights Strategy, Pipeline and Risk Disclosures
- Aquestive announces poster presentations on Anaphylm at AAAAI meeting
- Aquestive Therapeutics: Strengthened Leadership and Regulatory Clarity Underpin Buy Rating on Anaphylm Opportunity